Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Two Arm Phase II Study of Toripalimab Versus Toripalimab in Combination With Carboplatin and Nab-paclitaxel as a Novel Neoadjuvant Pre-Surgical Therapy for HNSCC

Next Previous
X
Search
Trial Profile

An Open Label, Two Arm Phase II Study of Toripalimab Versus Toripalimab in Combination With Carboplatin and Nab-paclitaxel as a Novel Neoadjuvant Pre-Surgical Therapy for HNSCC

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Toripalimab (Primary) ; Carboplatin; Paclitaxel
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HNSCC-002

    • Most Recent Events

    • 13 Apr 2023 Planned primary completion date changed from 1 Jan 2022 to 1 Dec 2023.
    • 14 Jul 2021 Planned initiation date changed from 1 May 2021 to 15 Jul 2021.
    • 14 Jul 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top